JP2025516358A5 - - Google Patents
Info
- Publication number
- JP2025516358A5 JP2025516358A5 JP2024565272A JP2024565272A JP2025516358A5 JP 2025516358 A5 JP2025516358 A5 JP 2025516358A5 JP 2024565272 A JP2024565272 A JP 2024565272A JP 2024565272 A JP2024565272 A JP 2024565272A JP 2025516358 A5 JP2025516358 A5 JP 2025516358A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- group
- alkyl
- cancer
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263339262P | 2022-05-06 | 2022-05-06 | |
| US63/339,262 | 2022-05-06 | ||
| US202263398769P | 2022-08-17 | 2022-08-17 | |
| US63/398,769 | 2022-08-17 | ||
| US202263429814P | 2022-12-02 | 2022-12-02 | |
| US63/429,814 | 2022-12-02 | ||
| US202363454477P | 2023-03-24 | 2023-03-24 | |
| US63/454,477 | 2023-03-24 | ||
| PCT/US2023/020987 WO2023215471A1 (en) | 2022-05-06 | 2023-05-04 | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025516358A JP2025516358A (ja) | 2025-05-27 |
| JP2025516358A5 true JP2025516358A5 (enExample) | 2026-05-01 |
Family
ID=86760567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024565272A Pending JP2025516358A (ja) | 2022-05-06 | 2023-05-04 | テトラヒドロイソキノリンヘテロ二官能性ｂｃｌ－ｘｌ分解剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250282771A1 (enExample) |
| EP (1) | EP4519260A1 (enExample) |
| JP (1) | JP2025516358A (enExample) |
| AU (1) | AU2023265886A1 (enExample) |
| CA (1) | CA3256666A1 (enExample) |
| MX (1) | MX2024013311A (enExample) |
| WO (1) | WO2023215471A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202527930A (zh) * | 2023-11-07 | 2025-07-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| TW202535872A (zh) * | 2023-11-07 | 2025-09-16 | 美商樹線生物科學公司 | 四氫異喹啉異雙功能ｂｃｌ－ｘｌ降解劑 |
| WO2025101575A1 (en) * | 2023-11-07 | 2025-05-15 | Treeline Biosciences, Inc. | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1888550T3 (pl) | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8889675B2 (en) | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| CN113660937A (zh) | 2019-02-08 | 2021-11-16 | 佛罗里达大学研究基金公司 | 治疗剂和治疗方法 |
| AU2020310147A1 (en) | 2019-07-10 | 2022-01-06 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| CN112707900B (zh) | 2019-10-24 | 2022-06-10 | 上海科技大学 | 蛋白降解剂及其在疾病治疗中的应用 |
| US12441722B2 (en) | 2020-01-15 | 2025-10-14 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| US20230167105A1 (en) | 2020-04-28 | 2023-06-01 | Recurium Ip Holdings, Llc | Bcl-2 protein inhibitors |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| US20250197387A1 (en) | 2021-09-17 | 2025-06-19 | Kymera Therapeutics, Inc. | Bcl-xl degraders and uses thereof |
-
2023
- 2023-05-04 EP EP23730236.9A patent/EP4519260A1/en active Pending
- 2023-05-04 JP JP2024565272A patent/JP2025516358A/ja active Pending
- 2023-05-04 US US18/859,011 patent/US20250282771A1/en active Pending
- 2023-05-04 AU AU2023265886A patent/AU2023265886A1/en active Pending
- 2023-05-04 CA CA3256666A patent/CA3256666A1/en active Pending
- 2023-05-04 WO PCT/US2023/020987 patent/WO2023215471A1/en not_active Ceased
-
2024
- 2024-10-28 MX MX2024013311A patent/MX2024013311A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025516358A5 (enExample) | ||
| JP2025517642A5 (enExample) | ||
| JP6823095B2 (ja) | 噴霧乾燥製剤 | |
| JP7326622B2 (ja) | Ｅｒｋ阻害剤としてのスピロ系化合物およびその使用 | |
| JP6547042B2 (ja) | 非選択的キナーゼ阻害剤 | |
| JP2024026074A (ja) | Ｊａｋ阻害剤を用いる化膿性汗腺炎の治療 | |
| WO2021197499A1 (zh) | 八氢吡嗪并二氮杂萘啶二酮类化生物 | |
| JP2025516359A5 (enExample) | ||
| JP2019163324A (ja) | Ｊａｋ及びｐｉ３ｋ阻害剤併用によるｂ細胞悪性腫瘍の処置 | |
| WO2021204111A1 (zh) | 作为dna-pk抑制剂的氨基嘧啶化合物及其衍生物 | |
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| JP2003521509A (ja) | 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤 | |
| JP2003525252A (ja) | Ｈｅｒ２抗体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤 | |
| JPWO2004080462A1 (ja) | ｃ−Ｋｉｔキナーゼ阻害剤 | |
| WO2020259573A1 (zh) | 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物 | |
| CN1313094C (zh) | Zd6474在制备在用电离辐射治疗的人体中治疗癌症的药物的用途 | |
| CN1886389B (zh) | 喹喔啉化合物 | |
| US20220227758A1 (en) | Imidazopyridine compound as irak4 inhibitor | |
| CN114404415A (zh) | 吲唑类化合物用于治疗银屑病的用途 | |
| WO2020151749A1 (zh) | 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物 | |
| WO2018084321A1 (ja) | Ｅｇｆｒ阻害及び腫瘍治療に有用な新規化合物 | |
| JP2022517110A5 (enExample) | ||
| CN101616584A (zh) | 前列环素衍生物 | |
| CN104364255A (zh) | 取代的黄嘌呤衍生物 | |
| JP2022540464A (ja) | Ｉｒａｋ４及びｂｔｋマルチターゲット阻害剤としてのオキサゾール化合物 |